Insiders at Galera Therapeutics, Inc. (NASDAQ:GRTX) recouped some losses this week after buying this year, still down US$28k

Published
August 12, 2022
NasdaqGM:GRTX
Source: Shutterstock

Some of the losses seen by insiders who purchased US$55k worth of Galera Therapeutics, Inc. (NASDAQ:GRTX) shares over the past year were recovered after the stock increased by 12% over the past week. The purchase, however, has proven to be a pricey bet, with losses currently totalling US$28k.

While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.

View our latest analysis for Galera Therapeutics

The Last 12 Months Of Insider Transactions At Galera Therapeutics

Over the last year, we can see that the biggest insider purchase was by Independent Director Linda West for US$55k worth of shares, at about US$2.74 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$1.36). While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We always take careful note of the price insiders pay when purchasing shares. Generally speaking, it catches our eye when an insider has purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. Linda West was the only individual insider to buy shares in the last twelve months.

You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
NasdaqGM:GRTX Insider Trading Volume August 12th 2022

Galera Therapeutics is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. Our data suggests Galera Therapeutics insiders own 1.5% of the company, worth about US$531k. We consider this fairly low insider ownership.

So What Does This Data Suggest About Galera Therapeutics Insiders?

There haven't been any insider transactions in the last three months -- that doesn't mean much. However, our analysis of transactions over the last year is heartening. The transactions are fine but it'd be more encouraging if Galera Therapeutics insiders bought more shares in the company. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. For example, Galera Therapeutics has 6 warning signs (and 3 which can't be ignored) we think you should know about.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Valuation is complex, but we're helping make it simple.

Find out whether Galera Therapeutics is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis